- Catalyst Pharmaceuticals Inc CPRX has received a favorable decision from the 11th Circuit Court of Appeals in its appeal to overturn a District Court decision upholding the FDA approval of another amifampridine product, Ruzurgi, despite existing Orphan Drug exclusivity for Catalyst's Firdapse (amifampridine).
- Amifampridine products are indicated for Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disorder that affects the connection between nerves and muscles.
- The FDA granted the approval of Ruzurgi to Jacobus Pharmaceutical Company Inc.
- Price Action: CPRX stock is up 8.76% at $5.46 during the market session on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: BiotechLong IdeasNewsHealth CareSmall CapLegalMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
